Biorestorative Therapies Inc Revenue Growth Rates (BRTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Biorestorative Therapies Inc   (NASDAQ: BRTX)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare
 

BRTX's Revenue Growth by Quarter and Year

Biorestorative Therapies Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BRTX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.03
FY 0.03

BRTXs Annual Revenue
Biorestorative Therapies Inc 's Revenue in the fiscal year 2025 $ 0.36 millions
Biorestorative Therapies Inc 's Revenue in the fiscal year 2024 $ 0.40 millions
Biorestorative Therapies Inc 's Revenue in the fiscal year 2023 $ 0.15 millions
Biorestorative Therapies Inc 's Revenue in the fiscal year 2022 $ 0.12 millions
Biorestorative Therapies Inc 's Revenue in the fiscal year 2021 $ 0.05 millions




BRTX Revenue first quarter 2026 Y/Y Growth Comment
Biorestorative Therapies Inc reported decrease in Revenue in the first quarter 2026 by -4.5% to $ 0.03 millions, from the same quarter in 2025.
The decrease in the first quarter 2026 Biorestorative Therapies Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 2335.61%.

Looking into first quarter 2026 results within Healthcare Facilities industry 25 other companies have achieved higher Revenue growth. While Biorestorative Therapies Inc ' s Revenue decline of -4.5% ranks overall at the positon no. 2526 in the first quarter 2026.


BRTX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -50 % 100 % -
3rd Quarter September - -95.65 % 666.67 % 0 %
2nd Quarter June - 233.33 % 50 % -14.29 %
1st Quarter March -4.5 % -25 % 33.33 % 50 %
FY   - -10 % 185.71 % -

Financial Statements
Biorestorative Therapies Inc 's first quarter 2026 Revenue $ 0.03 millions BRTX's Income Statement
Biorestorative Therapies Inc 's first quarter 2025 Revenue $ 0.03 millions Quarterly BRTX's Income Statement


BRTX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 100 % -82.61 % -33.33 %
3rd Quarter September - -96.67 % 155.56 % -50 %
2nd Quarter June - 900 % 125 % 100 %
1st Quarter March 43.25 % -25 % 100 % -
FY (Year on Year)   - -10 % 185.71 % -


Back to BRTX Growth rate Comparisons >> Back to BRTX Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #26
Healthcare Sector #359
Overall #2526

Revenue Y/Y Growth Statistics
High Average Low
64821.41 % 2335.61 % -94.47 %
(Mar 31 2015)   (Mar 31 2014)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #26
Healthcare Sector #359
Overall #2526
Revenue Y/Y Growth Statistics
High Average Low
64821.41 % 2335.61 % -94.47 %
(Mar 31 2015)   (Mar 31 2014)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Biorestorative Therapies Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1.0E+17 % 3.4587645138215E+15 % -100 %
 


BRTX's I. Quarter Q/Q Revenue Comment
Biorestorative Therapies Inc achieved in the I. Quarter 2026 below company average Revenue jump of 43.25% quarter on quarter, to $ 0.03 millions.

Although the I. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the I. Quarter surge, eclipses the -25% growth in the I. Quarter a year ago

Within Healthcare Facilities industry only one company achieved higher sequential Revenue growth. While Biorestorative Therapies Inc 's Revenue growth quarter on quarter, overall rank is 210.


Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #2
Healthcare Sector #53
Overall #210
Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #2
Healthcare Sector #53
Overall #210
Revenue Q/Q Growth Statistics
High Average Low
1.0E+17 % 3.4587645138215E+15 % -100 %
 


BRTX's I. Quarter Q/Q Revenue Comment
Biorestorative Therapies Inc achieved in the I. Quarter 2026 below company average Revenue jump of 43.25% quarter on quarter, to $ 0.03 millions.

I. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -25% in the I. Quarter a year ago.

Within Healthcare Facilities industry only one company achieved higher sequential Revenue growth. While Biorestorative Therapies Inc 's Revenue growth quarter on quarter, overall rank is 210.


Biorestorative Therapies Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 0.36 $ 0.36 $ 0.38 $ 0.61 $ 0.39
Y / Y Revenue Growth (TTM) -7.07 % -10.3 % 1.24 % 244.25 % 158.6 %
Year on Year Revenue Growth Overall Ranking # 83 # 47 # 44 # 183 # 433
Seqeuential Revenue Change (TTM) 1.01 % -6.18 % -36.65 % 54.78 % -2.49 %
Seq. Revenue Growth (TTM) Overall Ranking # 2526 # 1564 # 106 # 266 # 446


Cumulative Revenue growth Comment
Biorestorative Therapies Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2025. If the fiscal year would end in Mar 31 2026, Biorestorative Therapies Inc 's annual Revenue decline would be -7.07% year on year to $0 millions.

Within the Healthcare sector 30 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 47 to 83.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 26
Healthcare Sector # 31
Overall # 83

Revenue TTM Y/Y Growth Statistics
High Average Low
64821.41 %
 2335.61 %
-94.47 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 359
S&P 500 # 2526
Cumulative Revenue growth Comment
Biorestorative Therapies Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2025. If the fiscal year would end in Mar 31 2026, Biorestorative Therapies Inc 's annual Revenue drop would be -7.07% year on year to $0 millions.

Within the Healthcare sector 30 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 47 to 83.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 26
Healthcare Sector # 31
Overall # 83

Revenue TTM Y/Y Growth Statistics
High Average Low
64821.41 %
2335.61 %
-94.47 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 359
S&P 500 # 2526




Other Revenue Growth
Healthcare Facilities Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BRTX's Revenue Growth Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Trisalus Life Sciences Inc -0.03%$ -0.035 millions
Adma Biologics Inc -0.30%$ -0.304 millions
Vaso Corporation-0.54%$ -0.545 millions
60 Degrees Pharmaceuticals Inc -0.92%$ -0.922 millions
Cytosorbents Corporation-0.95%$ -0.945 millions
Conmed Corporation-1.31%$ -1.310 millions
Neuropace Inc -1.32%$ -1.316 millions
Bio techne Corp-1.35%$ -1.353 millions
Schrodinger Inc -1.62%$ -1.619 millions
United Therapeutics Corporation-1.62%$ -1.624 millions
Prokidney Corp -1.74%$ -1.739 millions
Sarepta Therapeutics Inc -1.89%$ -1.887 millions
Fortrea Holdings Inc -2.27%$ -2.272 millions
Ultragenyx Pharmaceutical Inc -2.36%$ -2.363 millions
Teladoc Health Inc -2.47%$ -2.467 millions
Fonar Corporation-2.55%$ -2.551 millions
Puma Biotechnology Inc -2.59%$ -2.593 millions
Coya Therapeutics Inc -2.61%$ -2.612 millions
10x Genomics Inc -2.76%$ -2.763 millions
Plus Therapeutics Inc -2.93%$ -2.927 millions
Infusystem Holdings Inc-2.97%$ -2.973 millions
Solventum Corporation-3.04%$ -3.043 millions
Milestone Scientific Inc -3.15%$ -3.153 millions
Organon and Co -3.50%$ -3.503 millions
Fulgent Genetics Inc -3.89%$ -3.894 millions
Igc Pharma Inc -3.94%$ -3.939 millions
Carlisle Companies Incorporated-3.99%$ -3.988 millions
Harvard Bioscience Inc -4.44%$ -4.437 millions
Castle Biosciences Inc -4.90%$ -4.897 millions
Prestige Consumer Healthcare Inc -4.95%$ -4.953 millions


About Biorestorative Therapies Inc Revenue Growth Rates (BRTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Biorestorative Therapies Inc (CIK 1505497).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-023126
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Biorestorative Therapies Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.